Andreas Kirsch Selected Research

Capecitabine (Xeloda)

10/2013

Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas Kirsch Research Topics

Disease

2	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 10/2013
1	Neoplasms (Cancer) 01/2017

Drug/Important Bio-Agent (IBA)

2	Bevacizumab (Avastin)FDA Link 01/2017 - 10/2013
1	Carcinoembryonic AntigenIBA 01/2017
1	Capecitabine (Xeloda)FDA Link 10/2013

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2017